BMY Stock and Options Trade Setup — Bristol-Myers Squibb Co.
S&P 500 · Pharmaceuticals (Oncology & Immunology) · High-liquidity options · Large cap · ~$105B
Bristol-Myers Squibb is navigating the Revlimid loss-of-exclusivity cliff while simultaneously launching a wave of next-generation products that collectively have the potential to more than offset the revenue loss. The Opdivo + Yervoy combination franchise continues to expand into new indications, and subcutaneous Opdivo (faster, more convenient) is capturing formulary share. The recent acquisitions of Karuna (KarXT for schizophrenia) and Mirati (KRAS inhibitor) add two near-term launches in large markets with limited competition. At current multiples — near decade-low P/E and a 5%+ dividend yield — BMY is pricing in a deeply pessimistic base case that appears asymmetrically rewarding for patient holders. Multiple pipeline read-outs over the next 18 months provide option-like upside catalysts on top of a cheap and well-covered dividend.
Score History & Signal Changelog
Preview dataThis page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.
Signal Breakdown
Today's Trade Card
Options Profile
Risks & Fundamentals
Every setup carries risk. Here's what could move BMY against you, plus the key stats that frame any position.
- 1.IRA drug price negotiation reducing Eliquis revenues (already designated for negotiation in 2026)
- 2.Pipeline setbacks in any major late-stage programme compressing the multiple further
- 3.Revlimid erosion materialising faster than management guidance if generics ramp more aggressively
BMY Options Setup — Frequently Asked Questions
Is BMY a good options trade today?+
Bristol-Myers Squibb Co. (BMY) currently has an Amora Edge Score of 67/100, ranking it top 25% of today's scan. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.
What is BMY's win rate on Stoptions.ai setups?+
BMY's historical win rate on closed Stoptions setups is 63%. Win rate is calculated as the percentage of past BMY trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.
What strike and expiry does Stoptions.ai suggest for BMY?+
The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.
How often is the BMY setup updated?+
Every 72 hours we refresh BMY's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If BMY drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.
What does the Amora Edge Score measure for BMY?+
The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to BMY: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is BMY outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. BMY currently scores 67.
How does BMY compare to other Pharmaceuticals (Oncology & Immunology) setups?+
BMY's sector rank and percentile against other Pharmaceuticals (Oncology & Immunology) tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Pharmaceuticals (Oncology & Immunology) Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.
Educational content only — not personalized investment advice. Options carry substantial risk.
Get a Friday recap including setups like BMY.
Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.
No spam. One email Friday afternoon. Unsubscribe in one click.